Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitemeipharma.com
CategoryBioTech
Phone858-792-6300
Emailmeiinformation@me...
Employees

Offices

San Diego, USA
11975 El Camino Real, Suite 101
San Diego, CA, 92130
USA

People

Managing Director
Non-Executive Director

Funding

TOTAL $1.11M
FUNDING TOTAL $1.11M
Venture Round, 5/2011
$1.11M

Tags

MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Recent Milestones

Videos

Screenshots

MEI Pharma screenshot
Above: MEI Pharma
Uploaded: 11/8/12

Sources

  1. SEC (sec.gov) [edit]
  2. MEI Pharma Announces $27.5 Million Private Placement (finance.yahoo.com) [edit]
Edit This Page
Last Edited 11/1/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy